Cargando…
miR-200b and miR-200c co-contribute to the cisplatin sensitivity of ovarian cancer cells by targeting DNA methyltransferases
Cisplatin is a first-line chemotherapy drug that is commonly used in the treatment of epithelial ovarian cancer (EOC). However, insensitivity to cisplatin markedly influences the outcomes of chemotherapy. MicroRNAs (miRNAs/miRs) have been demonstrated to modulate drug resistance in a number of types...
Autores principales: | Liu, Jue, Zhang, Xiaobo, Huang, Yuliang, Zhang, Qunfeng, Zhou, Jianbin, Zhang, Xiaodi, Wang, Xiaoxu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341622/ https://www.ncbi.nlm.nih.gov/pubmed/30675199 http://dx.doi.org/10.3892/ol.2018.9745 |
Ejemplares similares
-
Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer
por: Meng, Xiaodan, et al.
Publicado: (2016) -
The miR-200 family in ovarian cancer
por: Koutsaki, Maria, et al.
Publicado: (2017) -
MiR-200c and HuR in ovarian cancer
por: Prislei, Silvia, et al.
Publicado: (2013) -
Regulation of miR‐200c and miR‐141 by Methylation in Prostate Cancer
por: Lynch, Seodhna M., et al.
Publicado: (2016) -
The miR-200 Family: Versatile Players in Epithelial Ovarian Cancer
por: Muralidhar, Goda G., et al.
Publicado: (2015)